

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

[Propanc Biopharma Provides A Shareholder Update for 2021](#)

Mar 3 2021, 9:00 AM EST

[Professor Juan Marchal Believes Propanc Biopharma's Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients](#)

Feb 15 2021, 9:00 AM EST

[Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment](#)

Jan 28 2021, 9:00 AM EST

STOCK OVERVIEW

Symbol	PPCB	Propanc Biopharma, Inc.
Exchange	OTCQB	T: +61-03-9882-6723
Market Cap	836.12k	irteam@propanc.com
Last Price	\$0.23	
52-Week Range	\$0.22 - \$110.00	

03/04/2021 03:57 PM EST

INVESTOR RELATIONS

MANAGEMENT TEAM

James Nathanielsz

CEO, Executive Chairman and CFO

Dr. Julian Kenyon, M.D.

Chief Scientific Officer

Professor Klaus Kutz, M.D.

Chief Medical Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.